Drug repurposing using high-throughput screening identifies a promising drug combination to treat adrenocortical carcinoma
Drug repurposing using high-throughput screening identifies a promising drug combination to treat adrenocortical carcinoma |
|
https://doi.org/10.18632/oncotarget.26091
Antonio M. Lerario,
and Gary D. Hammer
|
| 33245-33246 |
The role of p16 as a biomarker in nonoropharyngeal head and neck cancer
The role of p16 as a biomarker in nonoropharyngeal head and neck cancer |
|
https://doi.org/10.18632/oncotarget.26053
Lucas K. Vitzthum,
and Loren K. Mell
|
| 33247-33248 |
Modeling and antitumor studies of a modified L–penetratin peptide targeting E2F in lung cancer and prostate cancer
Modeling and antitumor studies of a modified L–penetratin peptide targeting E2F in lung cancer and prostate cancer |
|
https://doi.org/10.18632/oncotarget.26064
Tazeem Shaik,
Gulam M, Rather,
Nitu Bansal,
Tamara Minko,
Olga Garbuzenko,
Zoltan Szekely,
Emine E. Abali,
Debabrata Banerjee,
John E. Kerrigan,
Kathleen W. Scotto,
and Joseph R. Bertino
|
| 33249-33257 |
Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer
Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer |
|
https://doi.org/10.18632/oncotarget.25947
Yudong Wang,
Zhijie Wang,
Sarina Piha-Paul,
Filip Janku,
Vivek Subbiah,
Naiyi Shi,
Kenneth Hess,
Russell Broaddus,
Baoen Shan,
Aung Naing,
David Hong,
Apostolia M. Tsimberidou,
Daniel Karp,
Charles Lu,
Vali Papadimitrakopoulou,
John Heymach,
Funda Meric-Bernstam,
and Siqing Fu
|
| 33258-33270 |
Glioblastoma in the setting of prior lower grade gliomas – insights from SEER database
Glioblastoma in the setting of prior lower grade gliomas – insights from SEER database |
|
https://doi.org/10.18632/oncotarget.26014
Ha Son Nguyen,
Benjamin Best,
Ninh B. Doan,
Michael Gelsomino,
Saman Shabani,
Ahmed J. Awad,
Mayank Kaushal,
and Martin M. Mortazavi
|
| 33271-33277 |
Metabolite quantification of faecal extracts from colorectal cancer patients and healthy controls
Metabolite quantification of faecal extracts from colorectal cancer patients and healthy controls |
|
https://doi.org/10.18632/oncotarget.26022
Gwénaëlle Le Gall,
Kiran Guttula,
Lee Kellingray,
Adrian J. Tett,
Rogier ten Hoopen,
E. Kate Kemsley,
George M. Savva,
Ashraf Ibrahim,
and Arjan Narbad
|
| 33278-33289 |
Single-cell transcriptomes reveal the mechanism for a breast cancer prognostic gene panel
Single-cell transcriptomes reveal the mechanism for a breast cancer prognostic gene panel |
|
https://doi.org/10.18632/oncotarget.26044
Shengwen Calvin Li,
Andres Stucky,
Xuelian Chen,
Mustafa H. Kabeer,
William G. Loudon,
Ashley S. Plant,
Lilibeth Torno,
Chaitali S. Nangia,
Jin Cai,
Gang Zhang,
and Jiang F. Zhong
|
| 33290-33301 |
The vesicular transfer of CLIC1 from glioblastoma to microvascular endothelial cells requires TRPM7
The vesicular transfer of CLIC1 from glioblastoma to microvascular endothelial cells requires TRPM7 |
|
https://doi.org/10.18632/oncotarget.26048
Dominique Thuringer,
Gaetan Chanteloup,
Pascale Winckler,
and Carmen Garrido
|
| 33302-33311 |
Role of textural heterogeneity parameters in patient selection for 177Lu-PSMA therapy via response prediction
Role of textural heterogeneity parameters in patient selection for 177Lu-PSMA therapy via response prediction |
|
https://doi.org/10.18632/oncotarget.26051
Zain Khurshid,
Hojjat Ahmadzadehfar,
Florian C. Gaertner,
László Papp,
Norbert Zsóter,
Markus Essler,
and Ralph A. Bundschuh
|
| 33312-33321 |
A safety study of newly generated anti-podoplanin-neutralizing antibody in cynomolgus monkey (Macaca fascicularis)
A safety study of newly generated anti-podoplanin-neutralizing antibody in cynomolgus monkey (Macaca fascicularis) |
|
https://doi.org/10.18632/oncotarget.26055
Takao Ukaji,
Ai Takemoto,
Ryohei Katayama,
Kengo Takeuchi,
and Naoya Fujita
|
| 33322-33336 |
Intratumor heterogeneity of HMCN1 mutant alleles associated with poor prognosis in patients with breast cancer
Intratumor heterogeneity of HMCN1 mutant alleles associated with poor prognosis in patients with breast cancer |
|
https://doi.org/10.18632/oncotarget.26071
Chie Kikutake,
Minako Yoshihara,
Tetsuya Sato,
Daisuke Saito,
and Mikita Suyama
|
| 33337-33347 |
Assessing the efficacy of androgen receptor and Sox10 as independent markers of the triple-negative breast cancer subtype by transcriptome profiling
Assessing the efficacy of androgen receptor and Sox10 as independent markers of the triple-negative breast cancer subtype by transcriptome profiling |
|
https://doi.org/10.18632/oncotarget.26072
Khalid N. Al-Zahrani,
David P. Cook,
Barbara C. Vanderhyden,
and Luc A. Sabourin
|
| 33348-33359 |
Loss of Gadd45b accelerates BCR-ABL-driven CML
Loss of Gadd45b accelerates BCR-ABL-driven CML |
|
https://doi.org/10.18632/oncotarget.26076
Xiaojin Sha,
Barbara Hoffman,
and Dan A. Liebermann
|
| 33360-33367 |
N-(2´-Hydroxyphenyl)-2-propylpentanamide (OH-VPA), a histone deacetylase inhibitor, induces the release of nuclear HMGB1 and modifies ROS levels in HeLa cells
N-(2´-Hydroxyphenyl)-2-propylpentanamide (OH-VPA), a histone deacetylase inhibitor, induces the release of nuclear HMGB1 and modifies ROS levels in HeLa cells |
|
https://doi.org/10.18632/oncotarget.26077
Arturo Contis-Montes de Oca,
Estefanía Rodarte-Valle,
Martha Cecilia Rosales-Hernández,
Edgar Abarca-Rojano,
Saúl Rojas-Hernández,
Manuel Jonathan Fragoso-Vázquez,
Jessica Elena Mendieta-Wejebe,
Ana María Correa-Basurto,
Ismael Vázquez-Moctezuma,
and José Correa-Basurto
|
| 33368-33381 |
Genetic disruption of calpain-1 and calpain-2 attenuates tumorigenesis in mouse models of HER2+ breast cancer and sensitizes cancer cells to doxorubicin and lapatinib
Genetic disruption of calpain-1 and calpain-2 attenuates tumorigenesis in mouse models of HER2+ breast cancer and sensitizes cancer cells to doxorubicin and lapatinib |
|
https://doi.org/10.18632/oncotarget.26078
James A. MacLeod,
Yan Gao,
Christine Hall,
William J. Muller,
Taranjit S. Gujral,
and Peter A. Greer
|
| 33382-33395 |
Meta-analysis of the likelihood of FOXC2 expression in early- and late-stage tumors
Meta-analysis of the likelihood of FOXC2 expression in early- and late-stage tumors |
|
https://doi.org/10.18632/oncotarget.26087
Tsutomu Kume,
and Tarek Shackour
|
| 33396-33402 |
Cancer stem cells in progression of colorectal cancer
Cancer stem cells in progression of colorectal cancer |
|
https://doi.org/10.18632/oncotarget.23607
Yujuan Zhou,
Longzheng Xia,
Heran Wang,
Linda Oyang,
Min Su,
Qiang Liu,
Jingguan Lin,
Shiming Tan,
Yutong Tian,
Qianjin Liao,
and Deliang Cao
|
| 33403-33415 |
Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy
Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy |
|
https://doi.org/10.18632/oncotarget.26058
Jack W. Singer,
Angela Fleischman,
Suliman Al-Fayoumi,
John O. Mascarenhas,
Qiang Yu,
and Anupriya Agarwal
|
| 33416-33439 |
Correction: Checkpoint inhibitor induced cardiotoxicity: managing the drawbacks of our newest agents against cancer
Correction: Checkpoint inhibitor induced cardiotoxicity: managing the drawbacks of our newest agents against cancer |
|
https://doi.org/10.18632/oncotarget.26113
Karina Brüstle,
and Bettina Heidecker
|
| 33440-33440 |
Correction: Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panel
Correction: Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panel |
|
https://doi.org/10.18632/oncotarget.26114
J. Tyson McDonald,
Athena Kritharis,
Afshin Beheshti,
Monika Pilichowska,
Kristine Burgess,
Luisel Ricks-Santi,
Elizabeth McNiel,
Cheryl A. London,
Dashnamoorthy Ravi,
and Andrew M. Evens
|
| 33441-33441 |
